Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $615 Billion
  • Q3 2024

Adar1 Capital Management, LLC has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $615 Billion distributed in 278 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Cytokinetics Inc with a value of $48.1B, Protagonist Therapeutics, Inc with a value of $44.2B, Bridge Bio Pharma, Inc. with a value of $36.9B, Ea Series Trust with a value of $35.2B, and Roivant Sciences Ltd. with a value of $34.9B.

Examining the 13F form we can see an increase of $85.2B in the current position value, from $530B to 615B.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $615 Billion
Healthcare: $433 Billion
ETFs: $6.5 Billion
Communication Services: $3.51 Billion
Utilities: $1.26 Billion
Technology: $995 Million
Industrials: $511 Million
Real Estate: $132 Million
Basic Materials: $121 Million
Other: $293 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
Tmt Acquisition Corp
-
$562 Million 0.09% of portfolio
-
Q4 2023 New
$140M
$505 Million 0.08% of portfolio
251,400
Q3 2024 Added 0.24%
$3.51B
$498 Million 0.08% of portfolio
17,252
Q3 2024 Reduced 16.46%
$819M
$511 Million 0.08% of portfolio
65,741
Q3 2024 Reduced 42.14%
$1.34B
$502 Million 0.08% of portfolio
20,400
Q3 2024 Reduced 37.04%
$0
$502 Million 0.08% of portfolio
10,000
Q3 2024 Reduced 81.13%
Soleno Therapeutics Inc
-
$505 Million 0.08% of portfolio
-
Q3 2024 Reduced 74.96%
Lexeo Therapeutics Inc
-
$517 Million 0.08% of portfolio
-
Q3 2024 Added 4,297.38%
$5.61B
$472 Million 0.08% of portfolio
5,100
Q3 2024 New
Vistagen Therapeutics Inc
-
$491 Million 0.08% of portfolio
-
Q3 2024 New
$2.02B
$485 Million 0.08% of portfolio
18,178
Q3 2024 Reduced 95.84%
$9.05B
$519 Million 0.08% of portfolio
3,894
Q3 2024 Added 10,147.37%
$3.23B
$436 Million 0.07% of portfolio
80,000
Q3 2024 Added 433.33%
Therapeuticsmd Inc
-
$448 Million 0.07% of portfolio
-
Q2 2024 Reduced 0.73%
$65.8M
$411 Million 0.07% of portfolio
416,958
Q3 2024 Reduced 21.72%
Biomx Inc
-
$441 Million 0.07% of portfolio
-
Q3 2024 New
$3.99B
$450 Million 0.07% of portfolio
7,100
Q3 2024 Reduced 92.22%
$1.61B
$373 Million 0.06% of portfolio
23,302
Q3 2024 Reduced 90.8%
$458M
$370 Million 0.06% of portfolio
24,307
Q3 2024 New
Spyre Therapeutics Inc
-
$369 Million 0.06% of portfolio
-
Q3 2024 Reduced 64.3%
$1.43B
$339 Million 0.06% of portfolio
15,000
Q3 2024 New
Adagio Med Hldgs Inc
-
$384 Million 0.06% of portfolio
-
Q3 2024 New
Casi Pharmaceuticals Inc
-
$399 Million 0.06% of portfolio
-
Q3 2024 Added 686.83%
$2.68B
$355 Million 0.06% of portfolio
23,100
Q3 2024 Added 1,676.92%
$314M
$373 Million 0.06% of portfolio
51,650
Q3 2024 New
Jasper Therapeutics Inc
-
$297 Million 0.05% of portfolio
-
Q3 2024 New
$3.99B
$331 Million 0.05% of portfolio
3,962
Q3 2024 Added 3,862.0%
Oak Woods Acquisition Corp
-
$333 Million 0.05% of portfolio
-
Q4 2023 New
Jvspac Acquisition Corp
-
$310 Million 0.05% of portfolio
-
Q3 2024 New
$90.4M
$280 Million 0.05% of portfolio
31,052
Q3 2024 Reduced 84.34%
$11.7M
$334 Million 0.05% of portfolio
315,192
Q3 2024 Reduced 11.27%
Polypid LTD
-
$323 Million 0.05% of portfolio
-
Q3 2024 Reduced 9.67%
$2.42B
$288 Million 0.05% of portfolio
10,000
Q3 2024 New
Vyne Therapeutics Inc
-
$287 Million 0.05% of portfolio
-
Q3 2024 Reduced 10.72%
Tourmaline Bio Inc
-
$289 Million 0.05% of portfolio
-
Q3 2024 Reduced 46.53%
$841M
$299 Million 0.05% of portfolio
114,981
Q3 2024 New
$65.5M
$236 Million 0.04% of portfolio
113,075
Q3 2024 Reduced 54.21%
Acelyrin Inc
-
$264 Million 0.04% of portfolio
-
Q3 2024 Added 5.9%
Oruka Therapeutics Inc
-
$274 Million 0.04% of portfolio
-
Q3 2024 New
$222M
$238 Million 0.04% of portfolio
40,634
Q3 2024 Added 118.06%
$1.35B
$266 Million 0.04% of portfolio
35,000
Q3 2024 Added 19.05%
$78M
$224 Million 0.04% of portfolio
240,557
Q3 2024 Added 34.97%
Tenax Therapeutics Inc
-
$216 Million 0.04% of portfolio
-
Q3 2024 New
$19.9B
$220 Million 0.04% of portfolio
978
Q3 2024 Reduced 91.19%
$1.99B
$227 Million 0.04% of portfolio
11,705
Q3 2024 Added 98.39%
$10B
$265 Million 0.04% of portfolio
3,634
Q3 2024 Reduced 91.39%
Iron Horse Acquisitions Corp
-
$255 Million 0.04% of portfolio
-
Q3 2024 New
$116M
$214 Million 0.03% of portfolio
97,955
Q3 2024 Added 656.12%
Contineum Therapeutics Inc
-
$172 Million 0.03% of portfolio
-
Q3 2024 New

Summary

  • Portfolio
  • No. of Stocks 278
  • Current Value $615 Billion
  • Prior Value $530 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 89 stocks
  • Additional Purchases 75 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 70 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email